[Book/FA chat to Rainier] Intersting that you're reading Murphy, who's very big on Biotechs. Most of the sector defies value investing, and fundimental analysis is a matter of assessing the science, their progress in the development/clinical trial/FDA approval cycle, the market potential of the drug or healthcare product, the number of potential winners, alliances with major drug firms, patents, likihood of bad trial results (lack of effacy, morbidity, etc).
I currently hold TRIBY (diagostic tests) and VICL, thinking of pulling trigger on ISIP & BTGN.
So, are you reading Murphy to assess how he values techs, balance your value focus, pick up on the psychology of part of the market, or a combo of the above.
Seriously, I'd be very interested in your assessment of the book. Scott
|
